Allogene Therapeutics, Inc. (ALLO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Allogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha

Allogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien

Chevron has secured new oil fields in Venezuela's Orinoco Belt, planning to more than double production to 600,000 barrels per day by 2026. The company will invest over $7 billion in the next five years through its stake in Petroindependencia. The expansion follows a new oil sector agreement approved by Venezuela's National Assembly and backed by the US government, aiming to attract private investment. Chevron is the only major US oil producer that remained in Venezuela after the 2007 nationaliz

Chariot Re, a reinsurance sidecar by MetLife (MET) and General Atlantic, raised $700M in equity and debt. The capital will expand its life and annuity reinsurance platform. Chariot Re has raised over $2B since its 2025 launch, reinsuring $20B in liabilities. MetLife and General Atlantic cited strong business momentum and investor confidence.

Chevron has agreed to updated terms for its Venezuelan joint ventures, planning a $7 billion investment over five years. This aims to double production to 600,000 barrels per day by 2026, with costs under $20 per barrel. Chevron's expanded footprint includes new acreage in the Orinoco Oil Belt, and production has already increased by 15% year-to-date.